[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"appetitive-behavior\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:appetitive-behavior":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,93,124,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100524164","validation-of-a-novel-cerebellar-striatal-satiety-circuit-in-humans-100524164",false,"NCT06105164","Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans","Inclusion Criteria:\n\n* Healthy individuals aged 18 to 65\n* BMI of 20-35.0 kg\u002Fm2\n* Normal or corrected-to-normal vision\n* Good general health\n* Ability to understand and willingness to sign written informed consent document\n\nExclusion Criteria:\n\n* Current and\u002For past medical conditions\n* Current and\u002For past eating disorder\n* On a restricted diet and\u002For taking weight loss medication(s)\n* History of bariatric surgery\n* Weight fluctuation \\>3% in past 3 months\n* Recent history of illicit recreational drug abuse\n* Current nicotine use\n* Intellectual disability\n* Conditions that might result in increased risks of side effects or complications from TMS or MRI",true,"ALL","18 Years","65 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study satiety in healthy individuals.\n\nTMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study, the investigators will be stimulating the brain to learn more about the role of the cerebellum in satiety.",[27,28],"Appetitive Behavior","Obesity","RECRUITING","2025-12-01",{"date":32,"type":33},"2025-12-05","ACTUAL",{"date":35,"type":33},"2024-12-05",{"date":37,"type":21},"2029-08",{"name":39,"class":40},"Brigham and Women's Hospital","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100555378","exercise-brain-activity-and-weight-maintenance-100555378","NCT06511310","Exercise, Brain Activity, and Weight Maintenance","Effects of Exercise Training on Brain Activity and Its Relation to Weight Maintenance and Appetite Regulation","Inclusion Criteria:\n\n* Age 18-70 years\n* Body mass index (BMI) \\>19 kg\u002Fm2 and body weight\\\u003C 250kg\n* Participants must have experienced a clinically significant weight regain, defined as over 10% of their maximum weight lost, within 1 to 5 years following their bariatric surgery. They will be asked to self-report their weight loss history. Participants must also provide the operative report from their bariatric surgery for reference.\n* In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations\n* Willing to adhere to the protocol requirements for the duration of the study\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Peripheral neuropathy with insensate feet\n* Recent blood donation within the last 2 months\n* Use of beta-blockers\n* Current pregnancy or breastfeeding\n* Active Heart or lung disease\n* Severe hypertension (systolic \\>160 mmHg or diastolic \\>90 mmHg)\n* Inability to exercise for any reason\n* Any known contraindication to exercise testing based on current ACSM guidelines\n* MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n* Presence of another neurologic disorder, which could impact findings (e.g. multiple sclerosis)\n* History of cardiovascular disease, stroke, congestive heart failure\n* Active hematological, renal, pulmonary or hepatic disorders\n* Active treatment for cancer\n* A history of active alcohol or substance abuse\n* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol\n* History of claustrophobia and inability to tolerate an MRI\n* Body weight \\>250kgr and largest body diameter of 70cm as there is a certain weight and diameter limit of the MRI scanner\n* Unwilling or unable to return for study visits, undergo neuropsychological testing and MRI imaging\n* Left-handedness","70 Years",{"count":51,"type":21},15,[24],"This study aims to explore how HIIT influences brain function, neural and molecular pathways related to weight control, setting the stage for future obesity intervention research.",[28,55,56,27],"Weight Gain","Bariatric Surgery Candidate","2025-08-27",{"date":59,"type":33},"2025-09-04",{"date":61,"type":21},"2025-09-15",{"date":63,"type":21},"2027-07-01",{"name":65,"class":40},"Joslin Diabetes Center",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":15,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":66},"100524392","food-for-thought-executive-functioning-around-eating-among-children-100524392","NCT06108128","Food for Thought: Executive Functioning Around Eating Among Children","Characterizing Top-down Dimensions of Appetite Self-regulation Among Preschoolers","Inclusion Criteria:\n\n1. Child ages 4 to 6 years of age\n2. Caregiver reporting primary responsibility for child feeding outside of childcare\n3. Caregiver legal guardian\n\nExclusion Criteria:\n\n1. Caregiver \\\u003C18 years of age\n2. Child major food allergies\n3. Child medication use, developmental disability, or medical conditions known to affect food intake and\u002For growth; color blindness\n4. Child in foster care","4 Years","6 Years",{"count":77,"type":21},125,[24],"Scientific knowledge of the cognitive-developmental processes that serve to support children's appetite self-regulation are surprisingly limited. This investigation will provide new scientific directions for obesity prevention by elucidating cognitive-developmental influences on young children's ability to make healthy food choices and eat in moderation.",[81,27,82,83],"Self-regulation","Eating Behavior","Child Obesity","2025-04-07",{"date":86,"type":33},"2025-04-10",{"date":88,"type":33},"2023-10-05",{"date":90,"type":21},"2025-12-31",{"name":92,"class":40},"Temple University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":15,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":66},"100558300","timing-and-resistance-exercise-impact-on-eating-and-metabolism-100558300","NCT06549322","Timing and Resistance Exercise: Impact on Eating and Metabolism","The Efficacy of Exercise Timing - Effects of Resistance Exercise on Eating Behavior and Energy Metabolism","Inclusion Criteria:\n\n* Age: 20-30\n* weight stable for at least 6 months\n\nExclusion Criteria:\n\n* Obesity (BMI \\> 30 kg\u002Fm² or body fat percentage \\> 25%)\n* Hypertension (blood pressure over 140\u002F90 mmHg)\n* Heart disease\n* Cancer\n* Liver or kidney diseases\n* Any other conditions that could potentially influence the study's outcomes","MALE","20 Years","30 Years",{"count":104,"type":21},18,[24],"Exercise timing (morning or evening) for optimal weight control is a research topic urgently addressed by scholars in the relevant field. Due to the better control of energy metabolism and physical activity levels in the morning, existing research on resistance exercise and eating behavior primarily focuses on experiments conducted in the morning, with only one study in the afternoon. No research has yet compared the potential differences between morning and evening resistance exercise. A one-year study aims to investigate the impact of morning and evening resistance exercise on physiological metabolism and eating behavior. Eighteen healthy male participants will be randomly assigned to a crossover design study, including AM exercise, PM exercise, and control (rest condition) trials. Variables including subjective appetite, appetite hormones (ghrelin, peptide YY), food preferences, ad libitum eating, dietary records, energy expenditure, and PBMCs circadian rhythm genes will be measured. This preliminary study through a multidimensional observation, the results will contribute to understanding the potential differences and mechanisms of morning and evening resistance exercise on physiological metabolism and eating behavior. In practical applications, conducting resistance exercise in the evening or at night aligns better with current lifestyles. The findings of this study can support the optimization of exercise benefits by validating the choice of exercise timing.",[108,109,27,110],"Circadian Rhythm","Energy Balance","Food Reward",[112,113],"resistance exercise","energy expenditure","NOT_YET_RECRUITING","2024-08-08",{"date":117,"type":33},"2024-08-12",{"date":119,"type":21},"2024-09-01",{"date":121,"type":21},"2025-12-30",{"name":123,"class":40},"National Taiwan Normal University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":66},"100555156","investigating-the-glycaemic-and-satiating-capacity-of-pulseon-enriched-foods-100555156","NCT06508424","Investigating the Glycaemic and Satiating Capacity of PulseOn® Enriched Foods","Investigating the Glycaemic and Satiating Capacity of PulseOn® Enriched Foods: a Randomised Control Trial","Inclusion Criteria:\n\n* over the age of 18y\n\nExclusion Criteria:\n\n* smoker \u002F recreational drug user\n* restrained eater (as determined by the three factor eating questionnaire (TFEQ-R18))\n* vegan\n* pregnant \u002F lactating\n* blood clotting disorder\n* taking medication for heart \u002F metabolic disease\n* pacemaker fitted\n* energy restricted diet or lost \\>5% body weight in the last 3 months\n* elite athletes\n* dysphagia\n* food allergy \u002F intolerance\n* disease \u002F inflammation of the GI tract",{"count":132,"type":21},50,[24],"The purpose of this randomised control trial is to determine whether consuming PulseOn enriched crackers for breakfast influences post-prandial glycaemic response and markers of appetite (hunger, fullness, desire to eat) over 4 hours, and energy intake at an ad libitum lunch meal on the same day. Healthy individuals with no underlying metabolic disease will be recruited to take part in this study.",[136,27,137],"Glycaemic Response","Energy Intake","2024-07-12",{"date":140,"type":33},"2024-07-18",{"date":142,"type":21},"2024-07",{"date":144,"type":21},"2024-11",{"name":146,"class":40},"Sheffield Hallam University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":66},"100517134","gut-hormone-leap2-in-metabolism-and-eating-behaviour-fixed-meal-testing-100517134","NCT06013592","Gut Hormone LEAP2 in Metabolism and Eating Behaviour: Fixed Meal Testing","LEAP2-meal","Inclusion Criteria:\n\n* Male or female between the ages of 18 and 60 years;\n* Without obesity with body mass index (BMI) 18.0-29.9 kg\u002Fm2 or with obesity with BMI 30.0-50.0 kg\u002Fm2;\n* Healthy as determined by medical history and vital signs;\n* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form;\n* Participant is able to read, comprehend and record information written in English.\n\nExclusion Criteria:\n\n* History of, or current abuse or dependence on alcohol or drugs;\n* Current smoker or less than 2 years since quitting (cigarette, cigars, e-cigarettes) or use of nicotine replacement therapy;\n* Significant current or past medical or psychiatric history that, in the opinion of the investigators, contraindicates their participation;\n* History of type 1 or type 2 diabetes mellitus;\n* History of ischaemic heart disease, heart failure, cardiac arrhythmia, peripheral vascular, cerebrovascular disease or uncontrolled hypertension;\n* Current diagnosis of anaemia or iron deficiency;\n* Body weight instability (change in body weight of more than 5% over the preceding 3 months);\n* Use of current regular prescription or over-the-counter medications that in the opinion of the Investigators may affect participant safety or outcome measures;\n* Clinically significant abnormalities in screening blood tests abnormalities which in the opinion of the study physician, is clinically significant e.g. diabetes mellitus, hypothyroidism, renal impairment, abnormal liver function tests \\[bilirubin, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)\\] \\>3x upper limit of normal, other than due to fatty liver disease; Current pregnancy or breast-feeding in female volunteers (the Investigators will recommend using contraception for the duration of the visits to avoid participant drop-out);\n* Pulse rate \\\u003C40 or \\>100 beats per minute OR systolic blood pressure \\>160 and \\\u003C100 OR diastolic blood pressure \\>95 and \\\u003C50 in the semi-supine position;\n* Volunteer has participated in a clinical trial and has received an investigational product within the following time period prior to the first experimental visit in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer);\n* Exposure to more than 3 new investigational medicinal products within 12 months prior to the scan;\n* Vegan, gluten or lactose-intolerant (as test meals in the paradigms may include animal products, dairy and wheat products);\n* Volunteers who have donated, or intend to donate, blood within three months before the screening visit or following study visit completion;\n* Known history of SARS-CoV-2 infection (Covid-19) in the last 4 weeks;\n* Ongoing symptoms suggestive of complications from previous SARS-CoV-2 infection ('long Covid-19') such as loss or change in sense of smell or taste, shortness of breath, palpitations, lethargy;\n* SCOFF questionnaire score \\>1\u002F5 indicating eating disorders (Luck et al. 2002);\n* DSM-V criteria for alcohol use disorder (AUD) \\>2\u002F11 indicating mild AUD (American-Psychiatric-Association 2013);\n* Participants who have had previous obesity surgery or are on medications for obesity;\n* Dutch Eating Behaviour Questionnaire (DEBQ) restraint score \\>3\u002F5 indicating highly restrained eating behaviour.","60 Years",{"count":156,"type":21},30,[24],"The goal of this interventional study is to measure the blood levels of the gut hormones LEAP2 and acyl ghrelin (AG), appetite and food intake after consuming liquid meals of different caloric sizes, in healthy adults with and without obesity.\n\nAG is a stomach-derived homone that increases appetite, and LEAP2 a liver-gut derived hormone that decreases appetite, which interferes the action of AG ant its receptor in the brain called the growth hormone secretagogue receptor (GHSR). Blood levels of AG and LEAP2 change in opposite directions after food intake (AG decreasing, LEAP2 increasing). AG is formed from an inactive version of hormone called desacyl ghrelin (DAG). Previous studies have shown that greater food intake leads to a greater decrease in blood levels of total ghrelin (AG + DAG), but this has not been studied for changes in blood AG or LEAP2 after eating. Blood levels of AG and total ghrelin when fasted and after food intake are lower, while blood levels of LEAP2 are higher, in adults with than those without obesity.\n\nThe main study questions are:\n\n1. Are there greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG after consuming larger meals (by amount of calories they contain)?\n2. Are greater decreases in appetite after connsuming larger meals related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG?\n3. Are greater decreases in food intake at a buffet lunch after consuming larger meals eaten a few hours previously related to greater increases in blood levels of LEAP2 and greater decreases in blood levels of AG?\n4. Do the above findings differ between adults without obesity and with obesity?\n\nAt each of 4 study days, healthy adults (without and with obesity) will consume one size of a single liquid meal containing different amounts of calories (0, 600, 900 (group without obesity only), 1200, 1800 (group with obesity only) kilocalories, of identical total volume) after an overnight fast and have measurements of blood LEAP2 and AG and appetite ratings from 0 to 180 min, and have food intake at an ad libitum lunch measured at 180 mins. Food will be weighed and converted into kilocalories.\n\nAll participants will attend for all 4 study visits in a randomised order to receive one of the meal sizes at each visit, so that all 4 meal zizes are consumed over all 4 study visits: 0, 600, 900 (group without obesity), 1200, 1800 (group with obesity) kcal.",[82,28,27],[161,162,163,164,165],"LEAP2","ghrelin","appetite","food intake","eating behaviour","2024-06-24",{"date":168,"type":33},"2024-06-26",{"date":170,"type":33},"2023-08-29",{"date":172,"type":21},"2025-08",{"name":174,"class":40},"Imperial College London"]